Dergiler / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 5

Low immunity against vaccine preventable diseases in Turkish HIV cohort

Sayfa
2311–2317
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

National campaigns can be launched for adult immunization and physicians should be aware of the importance of adult immunization.Key words: HIV, immunity, measles, mumps, rubella, tetanus

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: HIV infection increase the risk of serious disease resulting from common vaccine-preventable infections.
📊
Temel Bulgular & Veri:We aimed to investigate the immunity rates against measles, mumps, rubella, hepatitis A, B, and tetanus in newly diagnosed HIV patients.
💡
Sonuç & Katkı:National campaigns can be launched for adult immunization and physicians should be aware of the importance of adult immunization.Key words: HIV, immunity, measles, mumps, rubella, tetanus
🔬Tür:Araştırma Makalesi
📍Kapsam:2015 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: HIV infection increase the risk of serious disease resulting from common vaccine-preventable infections. Vaccinations are particularly important for HIV infected adults. We aimed to investigate the immunity rates against measles, mumps, rubella, hepatitis A, B, and tetanus in newly diagnosed HIV patients. Materials and methods: Patients who admitted to outpatient clinics of three centers with newly diagnosed HIV infection, between 1 January 2015 and 31 June 2017 were included. Measles, mumps, rubella, varicella zoster virus, hepatitis A, hepatitis B, and tetanus antibody levels were measured by commercial diagnostic kits. Demographical and laboratory data of the patients were recorded. Results: Five hundred and twenty-three patients were enrolled in the study. Of the patients 87% were male (n = 455) and the mean age was 38 ± 13 years. Serology was available for measles 74.2% (388/523), mumps 73.8% (386/523), rubella 77.8% (407/523), hepatitis A 88.5% (463/523), hepatitis B 97.7% (511/523), tetanus 8.6% (45/523), and VZV 79.9% (418/523). Seropositivity was 82% for measles, 75.6% for mumps, 92.1% for rubella. Of the patients whom all three of the components of the MMR vaccine was tested, 37.7% (127/337) were susceptible at least one and needed the vaccine. Mean age was lower in patients who are nonimmune to measles and mumps (p = 0.008). Younger patients were also nonimmune for hepatitis A, while older patients were nonimmune for hepatitis B. Conclusion: In our study we found that rates of nonimmunity can increase up to one third of the patients even though there is a national vaccination program. Nonimmune individuals should be detected and vaccinated in line with recent guidelines and response should be monitored because of the possibility of impaired immunity and possible suboptimal response. National campaigns can be launched for adult immunization and physicians should be aware of the importance of adult immunization.Key words: HIV, immunity, measles, mumps, rubella, tetanus

🔖

Bu Makaleye Atıf Yap

ÇETİNER, S., ESER, F., İNAL, A. S., ŞENTÜRK, G. Ç., CANDEVİR, A., KÖMÜR, S., TAŞOVA, Y., KUŞCU, F., KURTARAN, B., YILDIRIM, F. (2022). Low immunity against vaccine preventable diseases in Turkish HIV cohort. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 5, 2311–2317. https://ajindex.com/articles/609855

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nature Reviews Disease Primers 2015
  2. 1 (1): 15035. doi: 10.1038/nrdp.2015.35 2. Molton J, Smith C, Chaytor S, Maple P, Brown K et al. Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. Journal of Infection 2010
  3. 61 (1): 73-80. doi: 10.1016/j.jinf.2010.04.004 3. Crum-Cianflone NF, Wallace MR. Vaccination in HIV-infected adults. AIDS Patient Care and STDs 2014
  4. 28 (8): 397-410. doi: 10.1089/apc.2014.0121 4. Kernéis S, Launay O, Turbelin C, Batteux F, Hanslik T et al. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clinical Infectious Diseases 2014
  5. 58 (8): 1130-1139. doi: 10.1093/cid/ cit937 5. Ehren K, Hertenstein C, Kümmerle T, Vehreschild JJ, Fischer J et al. Causes of death in HIV-infected patients from the Cologne-Bonn cohort. Infection 2014
  6. 42 (1): 135-140. doi: 10.1007/s15010-013-0535-7 6. Kemper CA, Gangar M, Arias G, Kane C, Deresinski SC. The prevalence of measles antibody in human immunodeficiency virus-infected patients in northern California. Journal of Infectious Disesases 1998
  7. 178 (4): 1177-1180. doi: 10.1086/515679 7. Kemper CA, Zolopa AR, Hamilton JR, Fenstersheib M, Bhatia G et al. Prevalence of measles antibodies in adults with HIV infection: possible risk factors of measles seronegativity. AIDS 1992
  8. 6 (11): 1321-1325. doi: 10.1097/00002030-199211000- 00013 8. Choudhury SA, Hatcher F, Berthaud V, Ladson G, Hills E et al. Immunity to measles in pregnant mothers and in cord blood of their infants: impact of HIV status and mother’s place of birth. Journal of the National Medical Association 2008
  9. 100 (12): 1445-1449. doi: 10.1016/s0027-9684(15)31545-5 9. Lambert D, Dramé M, Rouger C, Brodard V, Nguyen Y et al. High prevalence of measles seronegativity in adults with HIV infection born in the era of measles vaccination in Northern France. AIDS 2015
  10. 29 (2): 241-243. doi: 10.1097/ QAD.0000000000000549 10. Llenas-García J, Rubio R, Hernando A, Arrazola P, Pulido F. Do HIV-positive adult immigrants need to be screened for measlesmumps-rubella and varicella zoster virus immunization? AIDS Care 2013
  11. 25 (8): 980-989. doi: 10.1080/09540121.2012.748881 11. Grabmeier-Pfistershammer K, Poeppl W, Herkner H, TouzeauRoemer V, Huschka E et al. High need for MMR vaccination in HIV infected adults in Austria. Vaccine 2014
  12. 32 (45): 6020- 6023. doi: 10.1016/j.vaccine.2014.07.114 12. Thio CL, Seaber